The Next Generation of Serotonergic Drugs

Our Approach

Functional Selectivity

Our lead compounds are novel, potent small molecule therapeutics that are “functionally selective” agonists of the 5-HT2C receptor and exhibit minimal off-target activity at the other receptors, including 5-HT2A and 5-HT2B. Our pilot in vitro and in vivo studies demonstrate that our lead compounds modulate 5-HT2C via a Gq-mediated signaling bias with minimal β-arrestin recruitment, while offering a favorable metabolic profile.